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Abstract
Background: Visceral leishmaniasis has been targeted for elimination as a public health problem (less than 1 case
per 10,000 people per year) in the Indian sub-continent by 2017. However, there is still a high degree of uncertainty
about the natural history of the disease, in particular about the duration of asymptomatic infection and the
proportion of asymptomatically infected individuals that develop clinical visceral leishmaniasis. Quantifying these
aspects of the disease is key for guiding efforts to eliminate visceral leishmaniasis and maintaining elimination once
it is reached.
Methods: Data from a detailed epidemiological study in Bangladesh in 2002–2004 was analysed to estimate key
epidemiological parameters. The role of diagnostics in determining the probability and rate of progression to
clinical disease was estimated by fitting Cox proportional hazards models. A multi-state Markov model of the
natural history of visceral leishmaniasis was fitted to the data to estimate the asymptomatic infection period and
the proportion of asymptomatic individuals going on to develop clinical symptoms.
Results: At the time of the study, individuals were taking several months to be diagnosed with visceral
leishmaniasis, leading to many opportunities for ongoing transmission. The probability of progression to clinical
disease was strongly associated with initial seropositivity and even more strongly with seroconversion, with most
clinical symptoms developing within a year. The estimated average durations of asymptomatic infection and
symptomatic infection for our model of the natural history are 147 days (95 % CI 130–166) and 140 days (95 % CI
123–160), respectively, and are significantly longer than previously reported estimates. We estimate from the data
that 14.7 % (95 % CI 12.6-20.0 %) of asymptomatic individuals develop clinical symptoms—a greater proportion
than previously estimated.
Conclusions: Extended periods of asymptomatic infection could be important for visceral leishmaniasis
transmission, but this depends critically on the relative infectivity of asymptomatic and symptomatic individuals to
sandflies. These estimates could be informed by similar analysis of other datasets. Our results highlight the
importance of reducing times from onset of symptoms to diagnosis and treatment to reduce opportunities for
transmission.
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Background
Visceral leishmaniasis (VL) in the Indian sub-continent
(ISC) is a disease caused by chronic infection with the
protozoan parasite Leishmania donovani, transmitted by
the Phlebotomus argentipes sandfly. Clinically manifest
visceral leishmaniasis, also called kala-azar (KA), is pro-
gressive with a high mortality rate, and characterized by
prolonged fever and an enlarged liver and/or spleen.
Clinical and laboratory diagnostics are imprecise [1–4],
partly because only a small proportion of infected indi-
viduals develop disease (so that the presence of infection
alone is not diagnostic), and partly because the clinical
features of VL overlap with those of other endemic dis-
eases (e.g. hyperreactive malarial splenomegaly, typhoid
fever and disseminated tuberculosis), so that clinical
presentation alone is not diagnostic. The current diagno-
sis generally relies on clinical features, specifically a fever
lasting at least 14 days and a palpable liver/spleen (hep-
atomegaly/splenomegaly), and elevated rK39 antibodies
(based on immuno-chromatographic assay) rather than
evidence of active current infection. This combination of
the duration of infection and rK39 rapid testing has high
sensitivity [5].
Epidemiologically, KA is spatially highly heterogeneous
with focal ‘hotspots’ of infection that move over time,
and periodic epidemics on a timescale of decades [6, 7].
The control campaign in the ISC, which has been run-
ning since 2005, has focused on elimination as a public
health problem (less than 1 new case per 10,000 people
per year), defined at local geographical scales (per sub-
district in both India and Bangladesh, known as an upa-
zila in Bangladesh). Progress has been made towards the
target by implementing novel case detection strategies,
rapid diagnostic testing and vector control activities. In
Bangladesh, KA incidence declined in all districts in the
8 years following the start of the control campaign
(2006–2013) from the previous 8 years (1998–2005) [8].
The highest number of cases was reported in 2006, after
which the annual number of cases decreased signifi-
cantly. In the period from 2008 to 2013, only 16 upazilas
had average incidence rates above the elimination target
(ranging from 1.06-18.25/10,000 people/year) [8]. In
Nepal, where KA was only endemic in south-eastern dis-
tricts neighbouring the state of Bihar in India and inci-
dence rates were much lower (1-10/10,000 people/year
in 2007–2008 [9]), the elimination target has been
reached for two consecutive years. However, Bihar,
which accounts for 70-80 % of the KA cases in India
[10], is still far from the target with an estimated inci-
dence of 22–29.8/10,000 people/year in 2006–2007 [11],
and more recent estimates of 1–5 cases/10,000 people/
year [10, 12].
Although vector control activities (in particular indoor
residual spraying (IRS)) are a pillar of the elimination
programme [13, 14], they appear to have uncertain and
variable effectiveness, likely due to sub-optimal imple-
mentation and, in some areas, insecticide resistance
[15–17]. However, a randomised control trial of IRS and
insecticide-treated bed nets in Bangladesh from 2006 to
2007 showed a 70-80 % reduction in sandfly density up
to 5 months post intervention [18], and recent model-
ling of IRS suggests that in low and medium endemicity
settings (5–10 KA cases/10,000 people/year) effective
IRS may be sufficient to reach the 1 case/10,000 people/
year elimination target [19].
Progress in KA case reduction over the past decade
has been largely attributed to improved timeliness of
diagnoses and more effective treatment [20]. Given that
the 'natural' epidemiology of the disease is typified by re-
current epidemics followed by long periods of low inci-
dence, and noting that the current control is dependent
on substantial external resources, effort and clinical
awareness, there is considerable potential for future re-
surgence without a sustained elimination effort [20, 21].
Other major issues for the elimination programme in-
clude high levels of under-reporting (the ratio of actual
to reported KA cases in the ISC is estimated to range
between 2:1 and 8:1 [22, 23]), and the unknown contri-
bution of asymptomatically infected individuals, who
potentially form a large infectious reservoir, to transmis-
sion [24, 25].
Mathematical and statistical modelling of infectious
diseases has a successful history of combining epidemio-
logical data, biological understanding and clinical know-
ledge into quantitative frameworks that can be used to
both interpret disease incidence (in terms of infection
patterns) and predict the impact of proposed interven-
tions. Visceral leishmaniasis is unusual in that there have
been relatively few previous modelling attempts, mostly
driven by the lack of quantitative data [26]. There are, to
our knowledge, only two recent, high quality, longitu-
dinal epidemiological studies: the KALANET bed net
trial in India and Nepal between 2006 and 2009 [27, 28],
and the studies of Bern et al. in Bangladesh from 2002
to 2010 [29–31]. Consequently, there is still a large
amount of uncertainty about the natural history of the
disease, in particular about its incubation period and the
proportion of asymptomatically infected individuals that
develop KA. From here on we treat the incubation
period as being synonymous with the duration of asymp-
tomatic infection, since in our modelling we do not ini-
tially distinguish between asymptomatically infected
individuals that develop KA and those that do not, but
we note that the duration of asymptomatic infection
may be different for the two groups and also test this
hypothesis (see Additional file 1). Previous estimates
for the incubation period have ranged from 2 to
6 months [32–34], while estimates for the proportion
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of asymptomatic individuals that progress to KA have
varied hugely, from 0.33 % [33] to 25 % [31]. Better
quantification of these aspects of the disease is critical
for developing effective models, guiding efforts to
eliminate VL and maintaining elimination once it is
reached.
Towards this end, we analyse the prospective, longitu-
dinal data from a 3-year study in Bangladesh in the
period 2002–2004 (details of the study and epidemio-
logical analyses have been reported elsewhere [29, 31]).
We use annual data on rK39 positivity and positivity of
the leishmanin skin test (LST), together with KA diagno-
sis, to estimate the rates of progression between different
disease states. The aim is to provide preliminary, quanti-
tative estimates of waiting times (i.e. times spent in each
state) and paths of progression that will feed into future
transmission model development.
Methods
Data
The study took place in a single community in Fulbaria
upazila, Mymensingh district, Bangladesh between Janu-
ary 2002 and June 2004. Fulbaria was chosen due to its
high reported KA incidence for the three years prior to
the study. In 2002 the community had a population of
approximately 12,000 people and was divided into 9
'paras' (sections), of 100–500 houses each. Cross-
sectional household surveys of the 3 paras with the high-
est reported KA incidence were conducted from January
to April in 2002, 2003 and 2004. All individuals who
lived at least 6 months in the study area in the 3 years
before the first survey in 2002 were included. The proto-
col was approved by the International Centre for Diar-
rhoeal Disease Research, Bangladesh (ICDDR,B) Research
and Ethical Review Committees and the Institutional Re-
view Board of the Centers for Disease Control and Pre-
vention (CDC).
The data recorded included demographic information
(age and sex), present and past KA cases (back to 1999),
and risk factors (such as sleeping location, bed net use,
diet, and animal ownership). For participants ≥ 3 years of
age, capillary blood samples were taken for serology
testing and the leishmanin skin test (LST) was applied
intradermally. The blood samples were tested by an
enzyme-linked immunosorbent assay (ELISA) with re-
combinant K39 (rK39) antigen [35, 36] and a modified
protocol that included a standard titration curve of a
pool of known positive sera on each plate of blood sam-
ples [37]. Concentration units (CU) were assigned to the
standard titration curve (with the highest concentration
on the curve assigned a value of 1000CU), and the op-
tical density of the serum specimens converted into CU.
The positive ELISA cut-off was set at 20CU—the 99th
percentile of the distribution of ELISA readings from 38
individuals living in a non-VL-endemic region of
Bangladesh. A second cut-off of 61CU was introduced
for diagnosis of active KA, with a sensitivity and specificity
of 97 % and 98.9 % respectively for sera from the study
population based on receiver-operator-characteristic ana-
lysis [37].
The antigen for the LST was a suspension of 5 × 106
promastigotes/mL of the WHO-approved MHOM/TN/
80/IPT1 strain of L. infantum. The test was applied fol-
lowing the standard protocol: 0.1 mL of antigen was
injected intradermally on the inside of the forearm and
48–72 h later the induration of the skin measured in
two perpendicular directions [38, 39]. In accordance
with international consensus, the LST result was deemed
positive if the mean of the two measurements was ≥
5 mm [31, 40]. There was evidence of loss of leishmanin
potency in this study in the 2003 and 2004 survey
rounds [30], and so at later time points the number of
individuals with positive LST reactivity is likely to be an
underestimate (testing showed that the L. infantum anti-
gen had a sensitivity of 70 % compared with L. amazo-
nensis antigen in 2004).
A past case of KA was defined as an illness with ≥
2 weeks of fever and at least one of: weight loss, abdom-
inal swelling or skin darkening, with clinical improve-
ment after 20 days of intramuscular injections of sodium
stibogluconate (SSG) (the treatment for KA prescribed
by national guidelines at the time). A present case of KA
was defined as one that fulfilled the same definition plus
splenomegaly and/or hepatomegaly and a positive rK39
ELISA result or rK39 dipstick test [29].
In total, data was collected on 2,410 out of 2507 indi-
viduals living in 509 houses in the 3 paras during the
study. Of these individuals, 47 % were male and 53 %
were female, and 2,152 had at least one rK39 ELISA or
LST reading between 2002 and 2004. There were 182
cases of KA from the start of 1999 to the end of the
study in June 2004: 125 cases with onset before 2002
and 57 with onset from 2002 to the end of the study
(see Table 1). There were only 5 relapses to active KA
following treatment, and the incidence of post kala-azar
dermal leishmaniasis (PKDL) was very low, with only 4
confirmed cases out of the 182 KA cases (all of which
were in 2004). Consequently, we have not included de-
velopment of PKDL in our modelling.
Statistical analysis
Following the identification of delays between onset of
symptoms and diagnosis and treatment [20, 41], a de-
scriptive analysis of the key time periods in the data was
performed. To investigate the impact of serological sta-
tus on progression to disease, we analysed the risk of
progression to KA for those with a particular sero-status
at baseline, and those who seroconverted during the
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study. Kaplan-Meier curves were plotted and Cox pro-
portional hazards regression models fitted to test for as-
sociations between (i) initial rK39 seropositivity and KA
and (ii) rK39 seroconversion and KA, following a previ-
ous analysis by Hasker et al. [28].
Hasker et al. analysed serology data from four dif-
ferent cohorts in two large studies—two from the
KALANET trial in India and Nepal, and two from
the Tropical Medicine Research Centre (TMRC) pro-
ject run in Bihar, India since 2008 [42, 43]—to deter-
mine the association between rK39 and direction
agglutination test (DAT) antibody titres and progres-
sion to KA. For the KALANET trial, rK39 ELISA re-
sults were available for 2006 only, so only the risk of
KA as a function of baseline seropositivity could be
assessed, but for the TMRC surveys blood samples
were tested using rK39 ELISA at each survey, so
seroconversion was also investigated. Hasker et al.
found that there was a strong association between
high rK39 titres at baseline and progression to KA,
and an even stronger association between seroconver-
sion to a high titre and subsequent progression.
In our analysis, we take the 2002 serology survey as
the baseline survey and the 2003 survey as the
follow-up survey. We use the rK39 ELISA cut-offs de-
scribed above to define seronegativity (rK39 ELISA
reading < 20CU), moderate seropositivity (20CU ≤
rK39 ELISA < 61CU) and strong seropositivity (rK39
ELISA ≥ 61CU). These differ slightly from the cut-offs
used in the Hasker study, in which the cut-off for
seropositivity was given by the mean optical density
of known negative sera plus two standard deviations,
and the cut-off for strong seropositivity was deter-
mined by the percentage point optical density with
the highest combined sensitivity and specificity for
identifying individuals diagnosed with KA in the last
2 years. Since the cut-off for strong seropositivity for
our data was determined using samples from individ-
uals with active KA as positive controls, it is likely
that it corresponds to a higher rK39 titre and is more
specific for KA. Nevertheless, the cut-offs for the
second TMRC cohort in [28], which was from a
higher endemicity region, correspond closely to those
used in our analysis.
For the analysis of KA progression risk with sero-
conversion, we classified seroconvertors from the
2002 survey to the 2003 survey into different groups.
Individuals that sero-deconverted from being either
strongly seropositive or moderately seropositive to
seronegative were grouped together (sero-deconver-
tors), as were those that remained either seronegative
or seropositive (non-convertors), who were taken as
the reference group. Individuals whose titre increased
between surveys were grouped into seroconvertors
(who went from being seronegative to seropositive)
and strong seroconvertors (who went from being
seronegative or seropositive to strongly seropositive).
People that were strongly seropositive at both surveys
were treated as a separate group.
Multi-state Markov model of natural history of VL
Multi-state Markov models provide an informative
way of analysing the natural history of a disease, by
describing how an individual moves through a series
of disease states (e.g. healthy, infected, recovered,
dead) in continuous time. The movement of individ-
uals between states is governed by a set of transition
intensities, qrs (r, s = 1,…, R), each of which represents
the instantaneous risk of moving from state r to state
s for r ≠ s ( qrr :¼ −
X
s≠r
qrs ), where R is the number of
states. The transition intensities may depend on time t
and a set of (potentially individual-specific) explanatory
variables z (i.e. qrs = qrs(t, z)), and are summarised in an
R × R matrix, Q, whose rows sum to zero. The aim of fit-
ting the multi-state model to data on observations of indi-
viduals’ disease states is to estimate the transition intensity
matrix Q.
Multi-state Markov models are particularly useful for
modelling panel data on disease progression, such as
that described above, where individuals are observed at
Table 1 Summary of the data
Year Reported number
of KA cases
Reported number
of KA deaths
Reported number
of non-KA deaths
rK39 ELISA LST
Positive Negative Positive Negative
1999 17 0 4 - - - -
2000 50 1 9 - - - -
2001 58 6 9 - - - -
2002 27 5 16 312 (19 %) 1301 (81 %) 530 (35 %) 1000 (65 %)
2003 24 2 14 284 (15 %) 1553 (85 %) 453 (26 %) 1294 (74 %)
2004 (to June) 6 2 0 252 (14 %) 1587 (86 %) 134 (19 %) 565 (81 %)
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approximately regular intervals, but the exact times be-
tween follow-up visits vary and limited information is
available about the individuals between follow-up visits.
This means that changes in individuals’ disease states
generally occur at unknown times.
Following Stauch et al. [33] and with a view to de-
veloping a transmission model, we model the natural
history of VL as shown in Fig. 1. Individuals are
classified into 5 different disease states—susceptible,
asymptomatically infected, symptomatically infected
(active KA), recovered/dormant, and dead—according
to their KA status and the results of the rK39 ELISA
and LST as shown in Table 2 (see Table A1 in Add-
itional file 1 for the full classification including cen-
sored states for missing tests). Susceptible individuals
(state 1) have negative rK39 ELISA and LST read-
ings, are not currently symptomatic, and their most
recent rK39 ELISA test was negative. If individuals
have a positive ELISA, but a negative LST and have
not previously suffered KA they are classed as being
asymptomatically infected (state 2). On development
of symptoms an individual is recorded as having KA
(state 3) and remains in this state from the date of
fever onset to the end of treatment or, if the individ-
ual is untreated, one year after the onset of symp-
toms (98 % of patients that have KA during the
study have a date of onset of symptoms and 91 %
have a date of start of treatment; prior to and after
the study period these data are often missing and so these
dates are recorded as unknown or uncertain). However,
asymptomatically infected individuals may also progress
to a 'recovered/dormant' state (state 4) without developing
symptoms. Recovered/dormant individuals are classified
as those who are LST positive, have recovered from their
KA symptoms or have sero-deconverted from positive to
negative rK39 ELISA. Recovered/dormant individuals may
relapse to KA or return to being susceptible. Deaths due
to KA and other causes (state 5) are included in the data-
set, so individuals may be absorbed from any of states 1 to
4 into state 5.
The transition intensity matrix for this 5-state model
of VL is
Q ¼
q11 q12 0 0 q15
0 q22 q23 q24 q25
0 0 q33 q34 q35
q41 0 q43 q44 q45
0 0 0 0 0
0
BBBB@
1
CCCCA
:
We will assume that the qrs are independent of the
number of individuals in each state, and thus are time-
independent. For this model, the proportion of those
asymptomatically infected who develop symptoms (ex-
cluding individuals that die) is the ratio of the transition
rate from asymptomatic infection to KA to the total rate
of progression to KA or recovery:
Probability of developing symptoms ¼ q23
q23 þ q24
:
ð1Þ
Fig. 1 Flow diagram for multi-state Markov model of natural history of VL
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Model fitting
The model was fitted using the multi-state modelling
package msm in R [44]. This package allows for the fact
that some observations are exact (such as dates of death)
and others are censored (such as the date of serocon-
version) (see Additional file 1 for further details). The
package estimates the transition intensity matrix Q
and its confidence intervals by maximising the likeli-
hood of the model given the data (see Additional file
1 for full details). The model also estimates the dura-
tions of the asymptomatic and symptomatic stages
(the waiting times in states 2 and 3). The BFGS
(Broyden-Fletcher-Goldfarb-Shanno) optimisation method
(a quasi-Newtonian hill-climbing method that uses ana-
lytic derivatives for the optimisation [45]) in the optim
function was used for finding the maximum likelihood.
The confidence interval for the proportion of asymptom-
atic individuals that develop KA was calculated by boot-
strap resampling of the data and refitting of the model
with 1000 bootstrap samples [44].
Results and discussion
Delays to treatment
Figure 2(a)-(c) show the distributions of onset-to-
treatment, onset-to-diagnosis and diagnosis-to-
treatment times for all KA patients for whom these
times were recorded, along with the median, mean
and standard deviation of each distribution. The me-
dian time of 120 days from onset to start of treat-
ment is much longer than figures recently reported
for Bangladesh (58 days) [20] and Nepal (55 days),
but is comparable with those for Bihar (104 days)
[41]. The discrepancy between our data and recently
reported figures likely reflects the poorer state of the
health care system and the greater cost of treatment
in Bangladesh at the time, and the fact that there was no
active detection programme for KA cases before 2005 [8,
46]. However, methodological differences between the
studies may also account for some of the difference; for ex-
ample, the dates of symptom onset and treatment from
1999 to 2002 were retrospectively ascertained in our study,
so may be subject to recall bias.
Risk of progression to KA
In the analysis of the association between rK39 sero-
status and progression to KA, 1,515 individuals who had
not had KA previously and who had a serological meas-
urement at baseline were included, amongst whom there
were a total of 43 KA cases. The Kaplan-Meier curve in
Fig. 3(a) illustrates that being highly seropositive at base-
line was much more predictive of progression to clinical
symptoms than moderate seropositivity or negative ser-
ology—29 % of strongly seropositive individuals pro-
gressed to KA compared to 3 % and 2 % of seropositive
and seronegative individuals. Testing these associations
using Cox regression modelling showed that there was
relatively little difference in the risk of progression for
seronegative and moderately seropositive individuals,
but a much higher hazard ratio (HR) for those with high
seropositivity (HR 17.7, 95 % CI 8.05-38.8, Table 3). This
matches the analysis of Hasker et al. [28], which found
hazard ratios for progression to KA ranging from 1.6 to
4.9 for seropositive individuals and from 7.7 to 39.6 for
strongly seropositive individuals compared to seronega-
tive individuals in 4 cohorts studied in Bihar, India and
Terai, Nepal. However, the proportion of strongly sero-
positive individuals progressing to KA in the Bangladesh
study was much higher than in all of the cohorts in [28]
(29 % compared to 1.1-7.7 %) except for the TMRC co-
hort in Muzaffapur, Bihar that was selected based on
high reported KA incidence in the year prior to the
study (where the proportion was 23.3 %).
As well as sero-status at baseline, seroconversion was
an important marker for progression to KA. The sero-
conversion analysis was performed using 1,372 individ-
uals that had rK39 ELISA readings from both the 2002
and 2003 surveys, 33 of whom developed KA. As ex-
pected from the figures shown in Table 3, a transition to
strong seropositivity from either negative or moderately
positive serology at baseline was associated with a high
progression rate to KA compared with no seroconver-
sion (HR 165, 95 % CI 74.6-365). Individuals that were
strongly seropositive at both surveys also had a high risk
of developing clinical symptoms (HR 61.5, 95 % CI 19.3-
196). Seroconversion to moderate seropositivity was
Table 2 Classification of individuals into different disease states in multi-state model
Disease state Description rK39 ELISA LST KA status Previous rK39 ELISA
1 Susceptible − − − −
2 Asymptomatic infected + − − + / −
3 Symptomatic infected (KA) + − + + / −
4 Recovered/dormant − − − +
+ / − + − + / −
+ − − (post-KA) + / −
5 Dead NA NA NA NA
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associated with an approximately 5-fold increase in risk
of KA over no seroconversion, but the difference in pro-
gression for sero-deconvertors and non-convertors was
not significant (Table 4). These results are similar to
those for the highly endemic villages in Muzaffapur,
Bihar in [28], which showed a hazard ratio for KA of
123.9 for individuals that became strongly seropositive
compared with those that remained seronegative. How-
ever, a far greater proportion of high-titre seroconvertors
progressed to KA in our data than in the previous study
(13/18, 72 % as opposed to 9/37, 24.3 %). Also, unlike in
this analysis, there was no significant association be-
tween moderate-titre seroconversion and progression to
KA in the previous study. This is likely to be partly due
to the differences, described in the Methods section, in
the definitions of the cut-off values for seropositivity and
strong seropositivity between the two studies.
The strong association between seroconversion to a
high rK39 antibody titre and progression to KA in the
study data suggests that rK39 ELISA could be used to
predict KA prior to the onset of symptoms. However,
since most high-titre seroconvertors who developed clin-
ical symptoms did so before the second survey (Fig. 3(b)),
more frequent testing would be required to use rK39
ELISA to pre-diagnose KA. Furthermore, even if prac-
tical constraints allowed for such testing, there is no
suitable prophylactic treatment available at present, due
to the toxicity of drugs currently used to treat KA.
Natural history of VL
We first fitted the Markov model in its simplest form
with constant transition intensities, i.e. treating individ-
uals in the same state as having the same risk of infec-
tion and disease. The estimated transition intensity
matrix for this 5-state model is
Q ¼
−0:22 0:21 0 0 0:005
0 −2:49 0:36 2:11 0:02
0 0 −2:61 2:48 0:13
0:31 0 0:01 −0:33 0:006
0 0 0 0 0
0
BBBB@
1
CCCCA
; ð2Þ
and the negative log-likelihood of the model is −
log L = 1760.5 for the fitted intensities. The movement
of individuals through the different disease states in the
model with the estimated transition intensities is simu-
lated in Additional file 2.
Proportion of asymptomatic individuals that develop KA
The estimated intensities show that for asymptomatically
infected individuals the probability of developing clinical
symptoms (from (1)) was
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Fig. 2 Delays to treatment. Distributions of (a) onset-to-treatment
time, (b) onset-to-diagnosis time, and (c) diagnosis-to-treatment time.
Sample sizes (n), medians, means and standard deviations (SDs): (a) n
= 147, median = 120 days, mean = 133 days, SD = 90 days; (b) n = 67,
median = 90 days, mean = 111 days, SD = 94 days; (c) n = 64, median =
12 days, mean = 24 days, SD = 35 days
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q23
q23 þ q24
¼ 0:36
0:36þ 2:11 ¼ 0:147;
with a 95 % bootstrap confidence interval (CI) of
0.126-0.200, and that recovery from KA with correct
treatment was nearly 20 times as likely as dying from
KA (q34/q35 = 19.5). This estimate for the proportion
of asymptomatic individuals that develop KA, 14.7 %
(95 % CI 12.6-20.0 %), is much larger than the figure
of 0.33 % (95 % CI 0.22-0.49 %) estimated by Stauch
et al. [33] from their SIRS model of VL transmission
fitted to the KALANET trial data, and the figure of
4 % used in the transmission model of Medley et al.
[20] based on the average progression to KA from
baseline seropositivity in the KALANET data [28]. It is,
however, similar to the proportion of DAT seroconvertors
Fig. 3 Kaplan-Meier curves for risk of progression to KA. Progression risk (with censoring) by (a) serology status at baseline, and (b) seroconversion
from baseline survey (2002) to second survey (2003). Dots show where individuals were lost to follow-up; dashed lines show 95 % confidence intervals
Table 3 Progression to KA depending on baseline rK39 sero-status. Hazard ratios and p-values estimated from fitted Cox proportional
hazards regression models
Baseline sero-status Total evaluated Progressors (%) Hazard ratio (95 % CI) p
Seronegative, rK39 ELISA < 20CU 1,283 28 (2 %) Ref. N/A
Seropositive, 20CU ≤ rK39 ELISA < 61CU 204 7 (3 %) 1.61 (0.71–3.70) 0.26
Strongly seropositive, rK39 ELISA ≥ 61CU 28 8 (29 %) 17.7 (8.05–38.8) 8.4 × 10−13
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that developed KA in high-endemicity villages in the
KALANET trial (10.1 %) [47], and the KA progression
rate of asymptomatics identified by rK39 and PCR positiv-
ity in a study in two highly endemic villages in Bihar in
2005–2006 (23 %) [24]. It also agrees reasonably well with
the 4:1 ratio of cases of seroconversion to KA reported by
Bern et al. [31] for the data from 2002 to 2004. The vari-
ation in these estimates may reflect differences in various
factors between the different study locations and periods,
including parasite virulence, the immune and nutritional
status of the host population, and the part of the epidemic
curve the study population was on (incidence was climb-
ing steeply in Fulbaria in 2000–2004 [7]). However, Stauch
et al.’s estimate may be a considerable underestimate of
the actual proportion that progress to KA due to the rapid
cycling of individuals through asymptomatic infection in
their model caused by fitting to cross-sectional data. It is
likely, therefore, that Stauch et al. underestimate the con-
tribution of KA patients to transmission relative to that of
asymptomatic individuals.
Average durations of asymptomatic infection and KA
The mean waiting times in the different disease states
for the estimated transition intensities are shown in
Table A2 in Additional file 1. The mean duration of
asymptomatic infection was 147 days (95 % CI 130–166
days) and that of symptomatic infection was 140 days
(95 % CI 123–160 days). Both these estimates are much
longer than estimates from previous models. Stauch et
al. [33] estimated that asymptomatic infection lasted on
average 72 days (95 % CI 69–75 days) and that KA pa-
tients that received successful first-line treatment were
cleared of parasites after 31 days and took 105 days on
average from developing symptoms to become DAT
negative and LST positive (i.e. to fully recover). Medley
et al. [20] assumed that the duration of asymptomatic
infection is 80 days in their model. Clearly, longer infec-
tion and disease durations can lead to increased trans-
mission, as there are more opportunities for sandflies to
become infected through feeding on humans. Based on
our estimates, asymptomatic individuals are likely to
contribute significantly to transmission even if their in-
fectivity to sandflies is low relative to symptomatic indi-
viduals, due to the long asymptomatic infection period
and the large ratio of asymptomatic to symptomatic in-
dividuals (although this proportion is smaller than that
estimated by Stauch et al. [33]). If our estimates of the
infection durations are representative of current high en-
demicity areas, more effort should be focused on redu-
cing time to treatment through active case detection and
early diagnosis, and greater surveillance of asymptomatic
infection is required to identify individuals that are likely
to develop KA and to estimate their contribution to
transmission.
Immunity
The estimated mean waiting time in the dormant/recov-
ered stage was 1110 days (95 % CI 988–1247 days),
which is much longer than that in the model of Stauch
et al., where individuals remained DAT positive after
asymptomatic infection or KA treatment for 74 days
(95 % CI 65–84 days) and LST-positive for 307 days
(95 % CI 260–356 days) on average, corresponding to a
total time in the dormant/recovered stage of 381 days.
We note that our estimate for the total time spent im-
mune or with dormant infection is also likely to be an
underestimate, due to the decrease in the sensitivity of
the LST over the course of the study. This suggests that
cellular immunity to the parasite can last for multiple
years after asymptomatic infection or successful treat-
ment for KA as reported elsewhere [48], rather than be-
ing lost within a year as suggested by Stauch et al.
Indeed the age distribution of LST positivity in 2002
(when the LST had highest sensitivity) (Figure A1 in
Additional file 1) shows an increase in the proportion of
LST positive individuals with age, and Bern et al. [31]
calculated from the data that there was a 48 % (95 % CI
38-59 %) increase in the chance of being LST positive
with each 10-year increase in age, which suggests that
cellular immunity wanes slowly. Of 530 individuals that
tested LST positive in 2002, only one developed KA over
the next two years, compared with 43 of the 1000
Table 4 Progression to KA depending on change in serology status from first survey to second survey. Hazard ratios and p-values
estimated from fitted Cox proportional hazard models. Sero-status: seronegative (−), seropositive (+), strongly seropositive (++)
Group First survey Second survey Total evaluated Progressors (%) Hazard ratio (95 % CI) p
Non-convertors - - 1103 10 (1 %) Ref. N/A
+ +
Sero-deconvertors +/++ - 145 2 (1 %) 1.54 (0.34–7.02) 0.58
++ +
Seroconvertors - + 95 4 (4 %) 4.73 (1.48–15.1) 0.009
Strong seropositives ++ ++ 11 4 (36 %) 61.5 (19.3–196) 3.5 × 10−12
Strong seroconvertors −/+ ++ 18 13 (72 %) 165 (74.6–365) <2 × 10−16
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individuals that tested negative (relative risk = 0.04, 95 %
CI 0.006-0.32), indicating that LST positivity represents
effective immunity against KA. Given the increasing
prevalence of LST positivity with age, its potentially long
duration and the strong protection it offers against KA,
control efforts should strive for 100 % detection and
treatment of KA cases, particularly among individuals
below 30 years of age who are less likely to be immune.
The LST should also form a routine part of epidemio-
logical studies to enable effective monitoring of levels of
immunity within the population and better prediction of
the risk of KA outbreaks, though this will require the
production of sufficient quality leishmanin antigen to
avoid issues associated with low antigen sensitivity [30].
Model fit
To assess how well the multi-state model fits the data
with the estimated transition intensity matrix in (2), we
compared the observed number and prevalence of indi-
viduals in each state during the study period from 2002
to 2004 to the expected number and prevalence from
the model. As shown in Table A7 and Figure A3 in
Additional file 1, the overall fit of the model is good,
with the observed and expected prevalences matching
very closely for susceptible individuals, KA patients
and recovered/dormant individuals, and fairly closely
for asymptomatically infected individuals and dead
individuals.
We also compared the model to a 6-state model in
which asymptomatically infected individuals were split
into two separate states—one for those who subse-
quently progressed to KA (‘pre-symptomatics’), and one
for those who recovered without developing symptoms
(‘asymptomatics’)—to determine whether there was a
difference in the duration of asymptomatic infection for
the two groups (see Additional file 1 for full details). Fit-
ting the 6-state model to the data gave similar results to
the 5-state model for the mean durations of the different
disease stages (127 days for KA, 95 % CI 113–143 days,
and 1108 days for the time spent immune or with dor-
mant infection, 95 % CI 987–1244 days) and the propor-
tion of infected individuals that develop symptoms
(13.8 %, 95 % CI 9.7–19.4 %), and fairly similar asymp-
tomatic infection durations of 135 days (95 % CI 109–
167 days) and 159 days (95 % CI 138–183 days) for pre-
symptomatics and asymptomatics.
Covariates
A number of factors may be associated with altered KA
risk, including sex, age and consistent use of bed nets
(Table A3 and Figure A2 in Additional file 1). Individ-
uals aged between 0 and 14 were at highest risk of KA
(9.9 %), with a significantly decreased KA incidence in
adults aged over 45, with only 2.8 % developing KA over
the course of the study. Males were found to have a
slightly higher incidence of KA than females (9.2 % com-
pared to 7.8 %), while the use of bed nets more than
halved the risk of KA (6.7 % compared to 14.7 %).
To further investigate the effects of these variables on
risk of infection and disease, we fitted the model with
each variable included as a covariate on the transition
intensities. The results are summarised in Table A4 in
Additional file 1, which gives hazard ratios for each co-
variate with 95 % confidence intervals. This analysis al-
lows us to investigate which parts of the disease
progression are affected by each covariate. For example,
the hazard ratios for q12 and q34 for bed net use are 0.72
(95 % CI 0.52–1.00) and 1.44 (95 % CI 1.06–1.96), sug-
gesting that bed net use reduces the risk of leishmanial
infection by 28 % and increases the chance of recovery
from KA by 44 % over no bed net use. This is potentially
due to bed nets preventing infected sandflies from biting
humans and either infecting or reinoculating them, and
suggests that, with proper and widespread use, bed nets
could form an effective part of VL control.
Performing a similar analysis on sex indicates that fe-
males have a lower rate of progression from asymptom-
atic infection to recovery/dormant infection (HR for q24
0.73, 95 % CI 0.57–0.94) and a higher rate of return
from recovery/dormant infection to susceptibility (HR
for q41 1.36, 95 % CI 1.07–1.72). While Table A3 and
Figure A2 in Additional file 1 suggest that the risk of KA
generally decreases with age, the risk does not decrease
linearly. Individuals aged 15–45 appear to be at in-
creased risk of infection compared with those aged 0–14
(HR for q12 1.31, 95 % CI 0.99–1.73), but more likely to
recover from asymptomatic infection without developing
KA (HR for q24 1.35, 95 % CI 1.03-1.77) and less likely
to recover from KA (HR q34 0.75, 95 % CI 0.56-1.00).
The risk of death from KA is higher for adults aged over
45 than children aged 0–14 (HR for q35 5.19, 95 % CI
1.28–21.0). As expected, the risk of death due to other
causes is much higher for adults aged over 45 than chil-
dren aged 0–14 (HRs for q15, q25 and q45 15.9, 95 % CI
4.5-55.4). Table A5 in Additional file 1 shows the prob-
ability of developing KA from asymptomatic infection
for the different groups for each covariate. The probabil-
ity is fairly similar across all groups and covariates, at
approximately 0.15-0.16, apart from for 0–14-year-olds,
who have a higher probability of developing symptoms
of 0.17, and those aged over 45, who have a much lower
probability of symptoms of 0.06. These differences have
implications for design of surveillance systems; for ex-
ample, they suggest that children are likely to be a more
sensitive indicator of continued transmission, whereas
most infection in adults is asymptomatic. Comparison of
the model with each of the covariates to the model with-
out any covariates using the likelihood ratio test and
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Akaike information criterion (Table A6 in Additional file
1) reveals that including each of the covariates signifi-
cantly improves the fit of the model to the data. The lar-
gest improvement in the fit is given by including age-
group as a covariate, which decreases the negative log-
likelihood for the model to − log L = 1720.7 (p = 1.8 × 10
−10 for the likelihood ratio test against the model with
no covariates).
Conclusions
By reanalysing a detailed dataset on the development of
clinical VL in Bangladesh in 2002–2004, we have been
able to provide an independent estimate for the propor-
tion of asymptomatically infected individuals who pro-
gress to KA of 14.7 % and an estimate for the
asymptomatic infection period of 147 days. Both these
estimates are similar to those reported in the literature
by other means [32, 34], but much higher and longer re-
spectively than those used in the main previous model-
ling studies [20, 33, 49].
Our analysis also shows that high rK39 levels, and in
particular seroconversion to a high rK39 titre, are good
predictors of progression to clinical VL, providing inde-
pendent support for the results from a previous study
[28]. This suggests that it may be possible to screen indi-
viduals to identify those who are likely to progress to
clinical VL, improve their access to treatment and po-
tentially reduce their infectious period and onward
transmission through targeted IRS.
The role of seroconverting and symptomatic individ-
uals in transmission depends not only on the proportion
of individuals in each state and the lengths of time they
are in each state, but also on their infectivity to sand
flies. The relative infectivity of asymptomatics and symp-
tomatics has rarely been studied, [50, 51], although one
xenodiagnostic study in Ethiopian patients and vectors
suggests that there may be marked changes in infectivity
with parasitaemia [52], a measure which was not noted
in this study.
We have also highlighted that the time from onset of
symptoms to treatment in this area of Bangladesh in the
early 2000s was considerably longer than in recent times
[41]. During the 2002–2004 study period, Bangladesh
experienced a major shortage of sodium stibogluconate,
the only KA treatment drug in use at the time [53]. The
shortage led to lack of supply in government health facil-
ities and price gouging in the private marketplace [54].
At the time the study began, the median time from onset
to treatment was 6 months and the only available drug
was provided by the project; this shortened to 3–4
months over the course of the study. Improvements in
drug availability after 2005, and especially after the im-
plementation of active case detection and treatment with
short course liposomal amphotericin B in Fulbaria [55],
may have helped to drive reductions in incidence in
Bangladesh by shortening the period symptomatic indi-
viduals spent in the community prior to treatment [20].
Despite our limited understanding of the natural his-
tory of VL [26], there are only two detailed epidemio-
logical studies of the progression of leishmanial infection
and disease. If we are to further refine control strategies
to bring VL to local elimination, such studies will be in-
valuable, particularly if they can assist in identifying indi-
viduals who will develop KA or who may contribute
most substantially to transmission.
Our intention is to use the results of our statistical
modelling to develop transmission dynamics models of
VL to evaluate the effect of potential interventions and
the feasibility of achieving the 2020 elimination goals. At
present, our estimate of the rate of infection, q12, is inde-
pendent of time and of the prevalence of infection, but
should be a function of the number of infectious sand-
flies, which itself is dependent on the infectiousness of
the human population. Within such a framework, we
can also consider the spatial kernel of transmission and
the impact of individual circumstances such as livestock
ownership, nutritional status and sleeping location. To
refine our estimates of the asymptomatic infection
period and proportion of infected individuals that de-
velop KA, and to assess the sensitivity and specificity of
the rK39 ELISA and LST used in the study, we need to
account for misclassification of individuals’ disease states
in the multi-state model due to errors in the test results.
This can be achieved using a hidden Markov model, in
which individuals’ observed states can be misclassifica-
tions of their true, underlying disease states.
The results of this study and the potential for future
development highlight the importance of detailed, longi-
tudinal studies for improving understanding of VL and
creating datasets that can be used for the design of inter-
ventions. As our understanding of the disease develops,
the requirements for such data change, indicating that
datasets such as these must be continually gathered.
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